Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MenACWY-TT is a quadrivalent conjugate vaccine designed to protect against invasive disease caused by *Neisseria meningitidis* serogroups A, C, W, and Y. The vaccine contains capsular polysaccharides from these four serogroups conjugated to tetanus toxoid as a carrier protein. It induces an immune response that generates protective antibodies against the targeted serogroups. MenACWY-TT has demonstrated high immunogenicity and an acceptable safety profile in infants (as young as 6 weeks), children, adolescents, and adults. It can be co-administered with other routine vaccines without compromising efficacy or safety. Originally developed by GSK Biologicals (now GSK), it was later acquired by Pfizer[1][5]. The primary indication is prevention of invasive meningococcal disease[1][5].
- Brand names
- NimenrixMenQuadfi
- Other names
- meningococcal quadrivalent tetanus toxoid conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)TT (Tetanus toxoid)
Beyond the preview
Go deeper on meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine.